Resistance arises through sophisticated cellular adaptations, including isoform switching of BRD4 and activation of compensatory signaling pathways such as PI3K/AKT and WNT. This resistance, coupled with the intricate transcriptional circuitry characteristic of solid tumors—distinct from hematological malignancies—has dampened hopes for BET inhibitors as monotherapies.

To address these challenges, the field is now pivoting towards next-generation strategies with enhanced specificity and efficacy. Among these, BD2-selective inhibitors aim to spare BD1, effectively reducing hematologic toxicities while maintaining robust anti-tumor effects. Proteolysis targeting chimeras (PROTACs) like ARV-771 and MZ1 have gained attention for their ability to degrade BET proteins entirely, potentially circumventing resistance associated with isoform variability.

Further innovation includes bivalent BET inhibitors that simultaneously engage both bromodomains, amplifying binding affinity and tumor suppression. Researchers are also exploring dual-function inhibitors that target BET proteins alongside kinases or histone deacetylases, as well as agents that disrupt BRD4-mediated phase separation at super-enhancers—critical hubs of oncogenic transcription.

Combination therapies represent a vital avenue to amplify therapeutic efficacy. Pairing BET inhibitors with PARP inhibitors has shown synergistic effects by exploiting DNA repair vulnerabilities, particularly in triple-negative breast and ovarian cancers. Similarly, combining BET inhibitors with androgen receptor antagonists improves outcomes in castration-resistant prostate cancer. Immune checkpoint inhibition in conjunction with BET targeting displays promising preclinical results, although toxicity remains a significant concern.

Clinical trials underscore both the potential and hurdles of BET inhibition. Agents like molibresib exhibited measurable activity in NUT carcinoma but required intermittent dosing to manage toxicity. Combinations such as ZEN-3694 with enzalutamide or talazoparib indicate early clinical signals of benefit, but many studies have been discontinued due to limited single-agent activity and pharmacokinetic limitations.

Looking forward, prioritizing the development of highly selective BET degraders, integrating predictive biomarkers such as MYC amplification or BRD4 dependency, and refining combination regimens stand as critical imperatives. Optimizing dosing to mitigate hematological adverse effects will be essential to unlock the full potential of BET-targeted therapies.

In summary, targeting BET proteins in solid tumors remains a vibrant and evolving frontier. First-generation inhibitors laid the conceptual groundwork, but overcoming inherent resistance and toxicity demands innovative next-generation molecules and strategic combinations. The path ahead hinges on biomarker-driven clinical trials and a deeper mechanistic understanding to translate this epigenetic vulnerability into tangible patient benefit.

Subject of Research: BET protein inhibition in solid tumors
Article Title: Inhibition of Bromodomain and Extra-Terminal Domain Proteins in Solid Tumors: Advances, Challenges, and Future Directions
News Publication Date: 2025
Web References: http://dx.doi.org/10.14218/GE.2025.00067
Keywords: BET proteins, BRD4, solid tumors, oncogenic transcription, PROTACs, BD2-selective inhibitors, combination therapy, drug resistance

BLBC, a highly aggressive subtype characterized by extensive copy-number alterations (CNAs), often harbors arm-level chromosomal imbalances whose contribution to tumorigenesis remains elusive. The researchers developed CRISPR-KOALA to conduct high-throughput bidirectional genetic screens directly in immunocompetent mouse models, overcoming previous barriers related to the complexity and scale of genes affected by aneuploidy.

By focusing on the ten most frequent human chromosome-arm alterations seen in BLBC, the team screened over 3,700 mouse orthologues of genes located on these arms. The screen identified 90 putative cancer driver genes—a majority of which had not been previously linked to cancer—revealing a diverse functional landscape shaping tumor biology. Among the implicated pathways were key signaling networks such as MAPK, HIPPO, and WNT, highlighting the heterogeneity intrinsic to BLBC progression.

Strikingly, manipulating these driver genes in Trp53-mutant mouse models was sufficient to bypass the need for whole-arm CNAs, suggesting that tumors exploit specific genes within broad chromosomal alterations to fuel oncogenesis. This finding challenges the traditional view that arm-level aneuploidies function merely as genomic chaos, instead presenting them as evolutionary selections for particular drivers.

One gene, PLGRKT, localized on chromosome 9p, emerged as a potent oncogene. The team showed that PLGRKT promotes tumor growth by enhancing mitochondrial robustness and boosting reactive oxygen species detoxification. This mechanistic insight connects chromosomal instability not only to genetic selection but also to metabolic adaptations that support cancer cell survival under stress.

Overall, this study delivers a transformative platform and a compendium of cancer drivers that illuminate how aneuploidy sculpts tumor heterogeneity. By delineating driver genes nested within widespread CNAs, it provides an invaluable resource for targeting breast cancer’s genetic complexity with greater precision.

The implications extend beyond breast cancer, offering a blueprint for dissecting arm-level aneuploidy in diverse malignancies. As cancer therapies increasingly focus on genetic vulnerabilities, CRISPR-KOALA represents a leap toward untangling the intricate link between chromosome-level alterations and oncogenic processes.

This work underscores the power of integrating genomic data with functional genetics in vivo, setting the stage for novel drug targets and therapeutic strategies aimed at the underexplored realm of aneuploidy-driven tumorigenesis.

Subject of Research: Chromosome instability and cancer driver genes in basal-like breast cancer

Article Title: Aneuploidy selects for the acquisition of driver genes in breast cancer

Article References:
Al-Zahrani, K.N., Langille, E.R., Nurtanto, J. et al. Aneuploidy selects for the acquisition of driver genes in breast cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10752-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10752-9